7 Of those who initiated ART in the third quarter of 2011 77% remained on

treatment, of the 23% that discontinued; 94% were lost to follow-up, 3% died and 3% decided to stop treatment.14 ART and PMTCT programmes were combined and administered by nurses at primary health facilities where women www.selleckchem.com/products/iwr-1-endo.html and children were already accessing health care; helping to target the hard to reach areas and reducing stigma.5 This could in turn encourage compliance and adherence. So revising the national guidelines, monitoring and evaluation systems, the supply chain and human resources strategies they made significant steps in providing an effective, equitable service with a broad health impact.5 The WHO anticipate B and B+ to be more cost effective than A, as first line once daily regimens are less costly now.5 The regimen recommended is Tenofavir, lamivudine or emtricitabine and efavirenz, (for ART and PMTCT). It is available as a single pill, fixed-dose combination and currently costs $180 per year with declines anticipated.13 Recent pharmacokinetic data is reassuring on the use of efavirenz in pregnancy but continued pharmacovigilence is essential. Simple regimens are needed for the best chance RAD001 purchase of success.15 However, option B+ does raise questions around how to guarantee long

term adherence, retention in treatment, safe transition to HIV care from antenatal care, development of drug resistance, increased drug exposure to the foetus and newborn, sustainability of service delivery in fragile primary care settings and the ongoing acceptability to women.13 Continued application and reflection of

and on this programme will in time reveal resolutions to these questions. The 2010 guidelines for infant feeding have not changed in the updated WHO 2013 guideline document.12 In countries where breastfeeding with the mother on ART and the infant receiving prophylaxis is considered the safest approach to ensuring survival of the newborn, mothers should exclusively breastfeed for the Aprepitant first 6 months of life and continue breastfeeding through weaning until 12 months of life.12 They can stop when a safe alternative is guaranteed after this age.12 The UK and Ireland adopt an individualised approach to PMTCT, but it is not without its own complications and the risk of MTCT still is not totally eliminated. Reasons for this are drug resistance, poor maternal adherence to treatment, late presenters in pregnancy and sero-conversion in pregnancy. Table 2 and Table 3 give details of the British HIV Association guidelines for the individualised management of HIV in pregnancy.11 In the UK and Ireland, from 2005 onwards more than 95% of women living with HIV are diagnosed antenatally through universal antenatal screening.15 This compares to a 30% antenatal diagnosis in the early 90s.